AB1647 NEUROBEHÇET DISEASE INCIDENCE IN NORTHERN SPAIN 1999-2019. A POPULATION-BASED STUDY

Background Behçet’s Disease (BD) incidence varies widely worldwide. Neurobehcet’s disease (NBD) is one of the most severe manifestations BD [ 1]. Data on NBD scarce and contradictory. Objectives To estimate in Northern Spain. Methods Population-based cohort study 120 patients diagnosed with Spain, between January 1, 1999, to December 31, 2019. Finally, 92 were included according 2013 International Criteria for 2]. was Consensus Recommendation criteria 3]. The 1999-2019 estimated by gender, age, year diagnosis. Annual expressed as cases per 100,000 people. Results 23 (25%) (15 women/8 men) (mean±SD age: 44±13.9 years). Ten (43.5%) had parenchymatous NBD, 10 non-parenchymatous 3 (13%) mixed NBD. Spain period 0.13 people [95% CI: 0.11-0.26] (0.14 [0.04-0.23] men, 0.24 [0.12-0.37] women). There variations annual incidences, a minimum value 0.08 2009-2010 maximum 0.26 2017-2018 ( Figure 1 ). highest rate observed men 20-29 years group (0.03 people) women 30-39 (0.07 people). On other hand, lowest 10-19 80-89 (0.008 When analyzed stratified there no statistical differences gender. studied showed an peak over last 20 years. A comparison different geographical areas made Table frequency ranges from 5.6 38%. It usually more frequent male young adults. Conclusion widely. epidemiological characteristics our series are similar except gender predominance. Like immune mediated diseases this cyclic pattern could possibly be related infectious environmental factors. References [1]Herrero-Morant A, et al Rheumatology. 2022; doi: 10.1093/rheumatology/keac097 [2]Davatchi F, al. J Eur Acad Dermatology Venereol. 2014;28:338-47. [3]Kalra S, Neurol. 2014;261:1662-76 1. Incidence neurobehçet’s residents Main clinical features areas. Author, Country Male n (%) Age at onset mean ± SD HLAB51+ % Ideguchi al.,2010 Japan 412 54 13 33 (61) (75) 36.9±11.9 35.8±10.3 123 (50) 16 (55) E. Bolek al., 2020 Turkey 419 26 6.2 225 (53.7) 39 (56.5) 29.2±9.0 27.4±9.2 104 (69.3) (65) Akman-Demir al.,1999 ND 200 155 (77.5) ND±ND 31.5±ND Houman al.,2013 Tunis 430 121 28.1 295 (68.6) 78 (64.5) 29.17±ND 29.02±ND 84 (19.5) 14 (33.3) Al-Araji 2003 Iraq 140 14.3 105 (70) 34.2±ND 34.1±ND Riera-Maestra et. 2010 360 (ND) 34±ND 36.3±ND Talarico 2012 Italy 117 38 72 (61.5) 36 25±4.0 77 (66) Domingos 2015 Portugal 138 25 18.1 45 (32.6) (40) 35.8±9.2 37.5±9.4 59 (42.9) (41.1) Sbaï France 109 (65.1) 31±ND Present study, 2022 58 (60.4) 8 (34.8) 38±13.9 43 (48.3) 5 (38.4) Abbreviations: BD: disease, NBD: Neurobehçet’s ND: Non data Acknowledgements: NIL. Disclosure Interests Alba Herrero-Morant: None declared, José Luis Martín-Varillas Grant/research support from: AbbVie, Pfizer, Lilly, Janssen, UCB, Celgene, Carmen Álvarez-Reguera: Lara Sanchez-Bilbao: David Martínez-López: Guillermo Suárez-Amorín: Raúl Fernández-Ramón: Iván Ferraz-Amaro: J. Hernández: Ricardo Blanco Speakers bureau: Abbvie, Roche, BMS, MSD, Roche.